ChadTangMD

Radiation Oncology • Houston, TX

Physician

Join to view full profile

Dr. Tang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tang's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Fax+1 713-563-6876

Education & Training

University of Texas M D Anderson Cancer CenterResidency, Radiation Oncology, 2013 - 2017
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 2012 - 2013
Stanford University School of MedicineClass of 2012

Certifications & Licensure

FL State Medical License 2021 - Present
GA State Medical License 2023 - 2026
OK State Medical License 2020 - 2026
TX State Medical License 2017 - 2026
AL State Medical License 2023 - 2025
AZ State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
TN State Medical License 2023 - 2025
WA State Medical License 2023 - 2025
American Board of Radiology Radiation Oncology
Join now to see all

Clinical Trials

MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK Trial Start of enrollment: 2020 Aug 19
WITHDRAWN
PHASE2
Stereotactic Body Radiation Therapy in Treating Patients with Oligometastatic Renal Cell Carcinoma Start of enrollment: 2018 Jun 14
SUSPENDED
PHASE2
Roles: Contact, Principal Investigator
Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer Start of enrollment: 2019 Nov 20
Completed
Phase 2
Roles: Contact, Principal Investigator
Systemic Therapy With or Without Local Consolidative Therapy in Treating Patients With Oligometastatic Solid Tumor Start of enrollment: 2018 Jul 31
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator, Contact
A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs) Start of enrollment: 2023 Oct 31
RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

2 citations
Clinical Characteristics, Management, and Outcomes of Patients with Renal Medullary Carcinoma: A Single-center Retrospective Analysis of 135 Patients.
Justin M Lebenthal, Panayiotis D Kontoyiannis, Andrew W Hahn, Zita D Lim, Priya Rao
European Urology Oncology. 2025-04-01
1 citations
Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase 2 Trial.
Jay P Reddy, Alexander D Sherry, Bryan Fellman, Suyu Liu, Tharakeswara Bathala
International Journal of Radiation Oncology, Biology, Physics. 2025-03-15
Safety and early outcomes of proton therapy and low-dose rate brachytherapy boost for patients with prostate cancer.
Osama Mohamad, Zakaria El Kouzi, Ramez Kouzy, Seungtaek Choi, Henry Mok
Brachytherapy. 2025-03-02

Press Mentions

Evaluating Metastasis-Directed Therapy in Oligometastatic Prostate CancerFebruary 14th, 2025
Metastasis-Directed Therapy for Prostate Cancer a Clear Winner in Meta-AnalysisFebruary 14th, 2025
KCA Brings Early-Career Clinicians Together for New Mentorship ProgramNovember 14th, 2024
Join now to see all